Table 1.
Baseline characteristics of all participants by starting dose of CPA
| No CPA | 10 mg CPA | 25 mg CPA | 50 mg CPA | 100 mg CPA | |
|---|---|---|---|---|---|
| Number of participants | 34 | 4 | 234 | 599 | 11 |
| - Amsterdam University medical center | 32 | 4 | 206 | 378 | 9 |
| - Ghent University Hospital | 2 | 0 | 27 | 195 | 2 |
| - University Hospital Florence | 0 | 0 | 1 | 26 | 0 |
| Age at initiation HT, year (IQR) | 27 [23-31] | 30 [19-57] | 25 [21-35] | 28 [23-42] | 34 [26-53] |
| Active smoking, %yes | 20.0 | 0.0 | 20.4 | 15.1 | 0.0 |
| Alcohol use >7 units/week, %yes | 9.1 | 0.0 | 5.9 | 7.3 | 27.3 |
| BMI, kg/m2 (IQR) | 22.7 [19.7-26.5] | 20.5 [17.6-20.6] | 22.7 [19.6-25.7] | 22.7 [20.5-25.9] | 23.0 [21.1-28.1] |
| Testosterone at initiation of HT, nmol/L (IQR) | 17.5 [14.0-26.0] | 20.0 [17.0-26.5] | 18.0 [13.0-22.0] | 19.0 [14.0-24.0] | 19.8 [16.5-25.2] |
| Prolactin at initiation of HT, U/L (IQR) | 0.1 [0.1-0.1] | 0.1 [0.1-0.2] | 0.1 [0.1-0.2] | 0.1 [0.1-0.2] | 0.1 [0.11-0.2] |
| Liver enzymes (IQR) | |||||
| AST, U/L | 21 [19-25] | 23 [19-24] | 21 [18-25] | 22 [18-26] | 21 [15-27] |
| ALT, U/L | 22 [16-29] | 15 [14-22] | 21 [16-28] | 21 [17-30] | 16 [13-25] |
| GGT, U/L | 18 [13-23] | 13 [11-19] | 17 [14-26] | 20 [15-28] | 16 [13-18] |
| ALP, U/L | 72 [54-82] | 63 [52-73] | 75 [63-89] | 70 [58-83] | 100 [100-100] |
| Lipid profile (IQR) | |||||
| LDL-C, mmol/L | 2.4 [1.8-3.5] | 1.8 [1.6-2.2] | 2.3 [1.8-2.9] | 2.5 [2.0-3.2] | 2.2 [1.8-3.0] |
| HDL-C, mmol/L | 1.2 [1.1-1.5] | 1.7 [1.6-1.8] | 1.3 [1.1-1.5] | 1.4 [1.1-1.6] | 1.4 [1.2-1.7] |
| Total cholesterol, mmol/L | 4.2 [3.5-5.5] | 3.8 [3.6-4.3] | 4.2 [3.6-4.9] | 4.4 [3.8-5.2] | 3.9 [3.7-4.8] |
| Triglycerides, mmol/L | 1.0 [0.9 -1.4] | 0.6 [0.6-0.9] | 1.0 [0.8-1.5] | 0.9 [0.7-1.3] | 0.7 [0.7-0.9] |
Values presented as median with 25-75 interquartile ranges (IQR). Active smoking (yes/no) and alcohol use >7 units (approximately 10 g of pure alcohol per unit) per week (yes/no) presented as percentages of corresponding dose.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CPA, cyproterone acetate; GGT, gamma-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; HT, hormone therapy; LDL-C, low-density lipoprotein cholesterol.